Clinical evaluation of heparin-coated circuits for routine coronary artery bypass grafting surgery: a prospective randomized study.
The aim of this study was to demonstrate the clinical and biological benefits of heparin-coated circuits in routine coronary artery bypass grafting (CABG). A prospective, randomized study was conducted in 80 patients undergoing routine CABG. Patients were randomized to either noncoated circuits (Group 1) or heparin-coated circuits (Group 2). A complete clinical evaluation was performed preoperatively at Days 0, 1, 2, and 3 and at discharge day and combined with extensive laboratory tests for hemostasis and inflammatory response. This study did not prove any major statistically significant clinical benefit of heparin-coated circuits in low risk patients. Postoperative bleeding, significantly less in the heparin-coated group, did not decrease significantly the number of transfused patients. Biological values were not changed significantly except for factor II and monocytes, which were higher in Group 2. Heparin-coated circuits offer minimal clinical and biological benefits for routine CABG surgery. However, they may prove beneficial for complex procedures or at-risk patients.
Collart
F
F
Department of Cardiac Surgery, Timone Hospital, University of Marseille, Marseille, France. fcollart@univ-aix.fr
Caus
T
T
Pomane
C
C
Pellissier
V
V
Chi
Y
Y
Montiès
J R
JR
Mesana
T
T
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D020099:Coated Materials, Biocompatible; D001026:Coronary Artery Bypass; D005260:Female; D006331:Heart Diseases / Q000601:surgery*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D006493:Heparin